Agile Therapeutics is a forward-thinking women's healthcare company dedicated
to fulfilling the unmet health needs of today's women.
Our product candidates are designed to provide women with contraceptive options
that offer freedom from taking a daily pill, without committing to a longer-acting
method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel
transdermal system), also known as AG200-15, is a once-weekly prescription
contraceptive patch that recently completed Phase 3 trials. Twirla is based on
our proprietary transdermal patch technology, called Skinfusion®, which is
designed to provide advantages over currently available patches and is intended
to optimize patch adhesion and patient wearability.
In addition to Twirla, we are developing a pipeline of other new transdermal
contraceptive products, including AG200-ER, which is a regimen designed to allow a
woman to extend the length of her cycle, AG200-SP, which is a regimen designed
to provide a shortened hormone-free interval, and AG890, which is a progestin-only
contraceptive patch intended for use by women who are unable or unwilling to take estrogen.